Novel Therapies for Relapsed and Refractory Neuroblastoma
AbstractWhile recent increases in our understanding of the biology of neuroblastoma have allowed for more precise risk stratification and improved outcomes for many patients, children with high-risk neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances in our understanding of neuroblastoma pathogenesis, the outcomes for children with relapsed neuroblastoma remain poor. These children with relapsed neuroblastoma, therefore, continue to need novel treatment strategies based on a better understanding of neuroblastoma biology to improve outcomes. The discovery of new tumor targets and the development of novel antibody- and cell-mediated immunotherapy agents have led to a large number of clinical trials for children with relapsed neuroblastoma, and additional clinical trials using molecular and genetic tumor profiling to target tumor-specific aberrations are ongoing. Combinations of these new therapeutic modalities with current treatment regimens will likely be needed to improve the outcomes of children with relapsed and refractory neuroblastoma. View Full-Text
Share & Cite This Article
Zage, P.E. Novel Therapies for Relapsed and Refractory Neuroblastoma. Children 2018, 5, 148.
Zage PE. Novel Therapies for Relapsed and Refractory Neuroblastoma. Children. 2018; 5(11):148.Chicago/Turabian Style
Zage, Peter E. 2018. "Novel Therapies for Relapsed and Refractory Neuroblastoma." Children 5, no. 11: 148.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.